Can a New CEO Fix Boeing?
https://www.fool.com/investing/2024/04/06/can-a-new-ceo-fix-boeing/?source=iedfolrf0000001
Apr 06, 2024 - We also talk with e.l.f. Beauty CEO Tarang Amin about how the company is succeeding.
0
Johnson & Johnson (JNJ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
https://www.zacks.com/stock/news/2252668/johnson-johnson-jnj-expected-to-beat-earnings-estimates-can-the-stock-move-higher?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2252668
Apr 09, 2024 - Johnson & Johnson (JNJ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0
Unlocking Q1 Potential of Johnson & Johnson (JNJ): Exploring Wall Street Estimates for Key Metrics
https://www.zacks.com/stock/news/2253845/unlocking-q1-potential-of-johnson-johnson-jnj-exploring-wall-street-estimates-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2253845
Apr 11, 2024 - Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Johnson & Johnson (JNJ), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.
0
3 Quarterly Releases to Watch Next Week
https://www.zacks.com/stock/news/2254814/3-quarterly-releases-to-watch-next-week?cid=CS-ZC-FT-stocks_in_the_news-2254814
Apr 12, 2024 - Earnings season is always an exciting time for investors, with companies finally revealing what's transpired behind closed doors. And concerning next week's docket, these three notable companies are scheduled to report.
0
Pharma Stock Roundup: JNJ to Buy Shockwave Medical, Other Pipeline & Regulatory News
https://www.zacks.com/stock/news/2254409/pharma-stock-roundup-jnj-to-buy-shockwave-medical-other-pipeline-regulatory-news?cid=CS-ZC-FT-analyst_blog|stock_roundup-2254409
Apr 12, 2024 - J&J (JNJ) is set to buy Shockwave Medical (SWAV). FDA approves AstraZeneca's (AZN) Enhertu for metastatic HER2-positive solid tumors.
0
JNJ Q1 earnings preview: A lot of moving factors expected to bring in-line results
https://seekingalpha.com/news/4089736-jnj-q1-earnings-preview-a-lot-of-moving-factors-expected-to-bring-in-line-results?source=feed_sector_healthcare
Apr 15, 2024 - Johnson & Johnson (JNJ) is set to announce Q1 earnings results, and analysts expect a profit of $2.65 (-1.1% Y/Y) on revenue of $21.39B (-13.4% Y/Y).
0
Top Stock Reports for NVIDIA, Alphabet & Johnson & Johnson
https://www.zacks.com/commentary/2257574/top-stock-reports-for-nvidia-alphabet-johnson-johnson?cid=CS-ZC-FT-research_daily-2257574
Apr 18, 2024 - Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Alphabet Inc. (GOOGL) and Johnson & Johnson (JNJ).
0
3 Unstoppable Dividend Stocks That Could Pay You for Life
https://www.fool.com/investing/2024/02/17/3-unstoppable-dividend-stocks-that-could-pay-you-f/?source=iedfolrf0000001
Feb 17, 2024 - There are no certainties in life or on the stock market. These companies' dividends are about as close as we can get.
0
Johnson & Johnson (JNJ) Rises Higher Than Market: Key Facts
https://www.zacks.com/stock/news/2229635/johnson-johnson-jnj-rises-higher-than-market-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2229635
Feb 21, 2024 - In the most recent trading session, Johnson & Johnson (JNJ) closed at $158.68, indicating a +0.52% shift from the previous trading day.
0
Pharma Stock Roundup: AZN's New Acquisition, FDA Updates for NVO & LLY and More
https://www.zacks.com/stock/news/2241296/pharma-stock-roundup-azn-s-new-acquisition-fda-updates-for-nvo-lly-and-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2241296
Mar 15, 2024 - AstraZeneca (AZN) is set to buy a private rare disease drugmaker. FDA delays decision on Lilly's (LLY) donanemab and approves Novo Nordisk's (NVO) Wegovy for reducing cardiovascular risks.
0
<Page 2